Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; Q2 is N or NR5a; one of Q1 and Q3 is CR5, and the other is N or NR5a; and the dashed circle denotes optional bonds forming an aromatic ring; Y1 is O or NR3; Y2 is —CO—, —SO2—, or —S(O(NH)—; Y3 is O or NR4a; provided that (1) Y1 and Y3 are not both O, and (2) when Y2 is C(O), Y1 is not O; L is a covalent bond or C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 and R4a are independently hydrogen, C1-6 alkyl, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: Use of a TNFR1-FADD-caspase8-caspase3 pathway inhibitor in preparation of a medicament for treating an immune system related disease caused by autoinducer, a method for screening a medicament for treating an immune system related disease caused by autoinducer and a method for treating an immune system related disease.

Abstract: A one-bead-two-compound combinatorial synthesis technique provides libraries of macrocyclic peptidomimetic compounds and compositions with use as ligands for the Ephrin type-A receptor 2 (EphA2). The one-bead-two-compound technique and libraries of macrocyclic compounds are useful as research tools in drug discovery and/or to treat or prevent a range of diseases or disorders.

Abstract: A rigid corneal contact lens comprises a front-surface optical zone and a back-surface optical zone: the front-surface optical zone comprises a front-surface central zone (1) and a defocusing zone (2) at the periphery of the front-surface central zone (1); the front-surface central zone (1) is spherical; the defocusing zone (2) has a radius of curvature decreasing from the outside of the front-surface central zone (1) continuously and a minimum radius of curvature which ranges from 95% to 50% of the radius of curvature of the front-surface central zone (1). Because of the structure of a human eye, the phenomenon of peripheral hyperopic defocus exist in human eyes, that is, central image points for an image are projected on macula foveal of retina and peripheral image points are projected behind retina. As shown in experimental evidences, peripheral hyperopic defocus is the main cause of myopia development which can be moderated by restraining peripheral hyperopic defocus.

Abstract: The present invention provides compounds of Formula (Ia) or (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; L is C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyallcyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 is hydrogen, C1-6 alkyl, C1-6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy, and the alkyl, by itself or as part of other moiety, is optionally substituted with deuterium partially or fully; R4 is C1-10 alkyl, C1-10 deuterated alkyl, C1-10 haloalkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, —(C1-6 alkylene)-(C

Abstract: The present invention provides compounds of Formula (Ia) or (Ib):Formula (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (Ia) and (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention relates to the use of at least two phenol derivatives jointly with at least one ancillary polymerization inhibitor which is different from these two phenol derivatives and particularly is selected from phenol derivatives, amine derivatives, thiazine derivatives, nitroso compounds, N-oxyl derivatives, metal salts, quinone derivatives, and mixtures thereof, to inhibit the polymerization of ethylenically unsaturated monomers comprising at least one heteroatom, it being also possible for a dispersant to be incorporated. The present invention also relates to a corresponding polymerization-inhibiting composition and to the corresponding process for preparing ethylenically unsaturated monomers comprising at least one heteroatom, and particularly acrylic monomers.

Abstract: The present disclosure relates to a method for determining optimal preservation temperature of aerobic denitrifiers in wastewater treatment for total nitrogen removal, and belongs to the technical field of environmental engineering. The method of the present disclosure comprises measuring the cell activity state of the aerobic denitrifier stored at different temperatures based on flow cytometry, and taking the preservation temperature closest to the cell activity state of the aerobic denitrifier during the pilot operation as the optimum preservation temperature, and the data obtained from the test uses the cell activity state and performance effects after activity recovery to verify reliability.

Abstract: A one-bead-two-compound combinatorial synthesis technique provides libraries of macrocyclic peptidomimetic compounds and compositions with use as ligands for the Ephrin type-A receptor 2 (EphA2). The one-bead-two-compound technique and libraries of macrocyclic compounds are useful as research tools in drug discovery and/or to treat or prevent a range of diseases or disorders.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: An ultrasonic diagnostic imaging system produces an image of shear wave velocities by transmitting push pulses to generate shear waves. A plurality of tracking lines are transmitted and echoes received by a focusing beamformer adjacent to the location of the push pulses. The tracking lines are sampled in a time-interleaved manner. The echo data acquired along each tracking line is processed to determine the time of peak tissue displacement caused by the shear waves at points along the tracking line, and the times of peaks at adjacent tracking lines compared to compute a local shear wave velocity. The resultant map of shear wave velocity values is color-coded and displayed over an anatomical image of the region of interest.